Isolation of a peptide for targeted drug delivery into human head and neck solid tumors

Area of Science:

• Oncology
• Biotechnology
• Drug Delivery

Background:

• Chemotherapy faces challenges with tumor specificity, leading to side effects that limit effective drug dosages.
• Targeted drug delivery systems are crucial for enhancing therapeutic efficacy and minimizing systemic toxicity.

Purpose of the Study:

• To isolate and characterize a novel peptide for targeted drug delivery into solid tumors.
• To evaluate the specificity and tumor penetration capabilities of the peptide HN-1 for head and neck squamous cell cancer (HNSCC).

Main Methods:

• Isolation of a 12-mer peptide (HN-1) with high specificity for HNSCC.
• Assessment of HN-1 internalization by HNSCC cells and nonmalignant cells.
• Evaluation of HN-1 binding affinity to primary HNSCC and its localization in HNSCC xenografts.

Main Results:

• The peptide HN-1 demonstrated internalization into HNSCC cells, indicating potential for drug translocation across cell membranes.
• HN-1 exhibited HNSCC specificity, with reduced uptake in nonmalignant oral keratinocytes and other cell types.
• HN-1 preferentially bound to primary HNSCC and localized within HNSCC xenografts, confirming tumor tissue penetration.

Conclusions:

• The tumor-specific peptide HN-1 is a promising candidate for targeted drug delivery into solid tumors.
• Peptide-based targeting offers a viable alternative to traditional antibody-based systems for cancer therapy.
• HN-1's properties support its utility in developing novel therapeutic strategies for HNSCC and potentially other cancers.